<DOC>
	<DOCNO>NCT00095277</DOCNO>
	<brief_summary>The purpose trial demonstrate benefit respect hematopoietic response subject anemia cancer randomize Darbepoetin Alfa every 4 week .</brief_summary>
	<brief_title>Darbepoetin Alfa Administered Once Every 4 Weeks Treatment Subjects With Anemia Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Eligibility Criteria : Subjects nonmyeloid malignancy Subjects chemotherapy Anemia cancer Eastern Cooperative Oncology Group ( ECOG ) status 0 2 Hemoglobin less equal 11.0 g/dL Adequate renal liver function Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>non-myeloid malignancy</keyword>
	<keyword>myeloma</keyword>
	<keyword>Anemia Cancer</keyword>
</DOC>